Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease

Abstract

Chronic kidney disease (CKD) will progress to end stage without treatment, the decline off renal function may not linear. A sensitive marker such as soluble urokinase-type plasminogen activator receptors (suPARs) may allow potential intervention and treatment in earlier stages of CKD.Objectives:This study was designed to measure plasma (suPAR) in patients with CKD with different stages and to find its correlation with the disease severity.Methods:This study was conducted on 114 subjects, 84 were patients with different stages and different causes of CKD, and 30 healthy subjects as controls. Blood urea, serum creatinine, serum high-sensitive C-reactive protein, estimated glomerular filtration rate, and 24hours proteinuria were measured, renal biopsy was done for all patients, and plasma (suPAR) was measured using enzyme-linked immunosorbent assay.Results:suPAR plasma levels were significantly higher in patients with CKD (7.9±3.82ng/mL) than controls (1.76±0.77ng/mL, P